Skip to content
Screener

Total debt at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$198.23M-7.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.26B+32,101%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$114.36M+395%
Regenxbio logo
RegenxbioRGNX
$68.95M-11.3%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.5M-97.6%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$410.95M+59.9%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $9.11M.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026. Open the filing →

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043

FAQ

What is Krystal Biotech, Inc.'s total debt?
Krystal Biotech, Inc. (KRYS) reported total debt of $9.11M in Q1 2026.
How has Krystal Biotech, Inc.'s total debt changed year-over-year?
Krystal Biotech, Inc.'s total debt decreased by 5.7% year-over-year, from $9.66M to $9.11M.
What is the long-term trend for Krystal Biotech, Inc.'s total debt?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total debt has grown at a 18.8% compound annual growth rate (CAGR), from $3.95M to $9.34M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.

Ask your AI about Krystal Biotech, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude